The use of nonabsorbable specific gastrointestinal antimicrobials, represents a new concept in the treatment of certain gastrointestinal disorders where bacterial overgrowth may play some role. The use of these agents allows: focusing treatment to bacteria involved at enteric and no systemic level and increased tolerability.
It is indicated for Irritable Bowel Disease, not enteroinvasive bacterial enterocolitis, traveler's diarrhea, bacterial enterocolitis resistant to symptomatic treatment; pseudomembranous colitis resistant to Vancomycin; diverticular disease with acute diverticulitis.
ENTERONOR®, Rifaximin, is administered only orally, the daily dose should be split into 2 or 3 doses. The recommended average adult dose is 600-800 mg / day for 5 to 7 days (maximum).
It is available in packages with 16 and 32 tablets with Rifaximin 400 mg.